Wanbang Pharmaceutical (301520.SZ): Hefei Quanxiang plans to participate in a 10 million yuan private equity fund investment, laying out the field of cell and gene industry.

Wanbang Medicine (301520.SZ) announced that the Hefei Qunxiang Qiming Enterprise Management Partnership (Limited Partnership) controlled by the company...

Zhitong FinanceNov 26 06:51 ET

万邦医药 (301520.SZ): The company-controlled partnership enterprise proposes to subscribe for private equity fund shares.

Gelonghui, November 26th - Wanbang Pharmaceutical (301520.SZ) announced that Hefei Qunxiangqiming Enterprise Management Partnership Enterprise (Limited Partnership) controlled by the company, referred to as "Hefei Qunxiang", signed the "Shenzhen Songhe Cell and Gene Industry Private Equity Fund Partnership Enterprise (Limited Partnership) Partnership Agreement" and related documents with Shenzhen Songhe Capital Management Co., Ltd. on November 22, 2024. Hefei Qunxiang, as a limited partner, subscribed to the Shenzhen Songhe Cell and Gene Industry Private Equity Fund Partnership Enterprise (Limited Partnership) (tentatively named, finally approved by the industrial and commercial registration authority as

Gelonghui FinanceNov 26 06:03 ET

Wanbang Pharmaceutical: Report for the third quarter of 2024

SZSIOct 24 12:00 ET · Announcements

Wanbang Pharmaceutical (301520.SZ) released its performance for the first three quarters, with a net income of 77.7975 million yuan, a year-on-year increase of 0.63%.

Wanbang Pharmaceutical (301520.SZ) released its third quarter report for 2024. In the first three quarters, the company achieved revenue...

Zhitong FinanceOct 24 10:00 ET

万邦医药 (301520.SZ): The net income for the first three quarters was 77.7975 million yuan, a year-on-year increase of 0.63%.

Geneva News, October 24th - Wanbang Pharmaceutical (301520.SZ) released the third quarter report for 2024, with a revenue of 0.293 billion yuan in the first three quarters, a year-on-year increase of 21.88%; net income attributable to shareholders of listed companies was 77.7975 million yuan, a year-on-year increase of 0.63%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 55.8997 million yuan, a year-on-year decrease of 21.08%; basic earnings per share were 1.17 yuan.

Gelonghui FinanceOct 24 09:37 ET

Is Anhui Wanbang Pharmaceutical Technology Co.,Ltd.'s (SZSE:301520) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Simply Wall StSep 28 22:50 ET